GT200100014A - Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo. - Google Patents
Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo.Info
- Publication number
- GT200100014A GT200100014A GT200100014A GT200100014A GT200100014A GT 200100014 A GT200100014 A GT 200100014A GT 200100014 A GT200100014 A GT 200100014A GT 200100014 A GT200100014 A GT 200100014A GT 200100014 A GT200100014 A GT 200100014A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- inhibit
- pharmaceutical compositions
- proteinkinases
- instructions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
SE DESCRIBEN LOS COMPUESTOS DE LAS AMIDAS QUE MODULAN Y/O INHIBEN LA ACTIVIDAD DE CIERTAS PROTEINAS CINASA. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN SON CAPACES DE ACTUAR COMO MEDIADOR DE LA SEÑAL DE TRANSDUCCION DE LA TIROSINA CINASA CON EL FIN DE MODULAR Y/O INHIBIR LA PROLIFERACION CELULAR INDESEADA. LA INVENCION TAMBIEN VA DIRIGIDA AL USO TERAPEUTICO O PROFILACTICO DE LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS, Y A LOS METODOS PARA EL TRATAMIENTO DEL CANCER Y DE OTRAS ENFERMEDADES ASOCIADAS A LA ANGIOGENESIS Y/O PROLIFERACION INDESEADA, TAL COMO LO SON LA RETINOPATIA DIABETICA, NEOVASCULARIZACION DEL GLAUCOMA, ARTRITIS REUMATOIDE, Y SORIASIS, MEDIANTE LA ADMINISTRACION DE CANTIDADES EFICACES DE DICHOS COMPUESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17705900P | 2000-01-21 | 2000-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200100014A true GT200100014A (es) | 2002-03-14 |
Family
ID=22647011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200100014A GT200100014A (es) | 2000-01-21 | 2001-01-19 | Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo. |
Country Status (14)
Country | Link |
---|---|
US (2) | US6635641B2 (es) |
EP (1) | EP1252146A1 (es) |
JP (1) | JP2003529558A (es) |
AR (1) | AR029222A1 (es) |
AU (1) | AU2001234484A1 (es) |
BR (1) | BR0108025A (es) |
CA (1) | CA2394703A1 (es) |
CO (1) | CO5280047A1 (es) |
GT (1) | GT200100014A (es) |
HN (1) | HN2001000008A (es) |
MX (1) | MXPA02007102A (es) |
PA (1) | PA8510201A1 (es) |
PE (1) | PE20011047A1 (es) |
WO (1) | WO2001053274A1 (es) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01007099A (es) | 1999-01-13 | 2002-03-27 | Univ New York State Res Found | Metodo novedoso para disenar inhibidores de la proteina cinasa. |
AU7989400A (en) | 1999-10-01 | 2001-05-10 | Smithkline Beecham Corporation | Compounds and methods |
DE10021246A1 (de) * | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
CA2462442A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
JP4623962B2 (ja) * | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
EP1463505A2 (en) * | 2001-12-13 | 2004-10-06 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
JP2005538975A (ja) * | 2002-07-03 | 2005-12-22 | アステックス テクノロジー リミテッド | p38MAPキナーゼ阻害薬としての3−(ヘテロ)アリールメトキシピリジン類およびそれらの類縁体 |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AU2003250701A1 (en) | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
ES2298563T3 (es) * | 2002-10-09 | 2008-05-16 | Critical Outcome Technologies, Inc. | Inhibidores de proteinas tirosina cinasas. |
CN1506359A (zh) * | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
JP4613157B2 (ja) * | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
WO2004092217A1 (en) * | 2003-04-17 | 2004-10-28 | Pfizer Inc. | Crystal structure of vegfrkd: ligand complexes and methods of use thereof |
WO2004098528A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
WO2005039564A1 (en) * | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
PL1765327T3 (pl) | 2004-06-17 | 2015-01-30 | Cytokinetics Inc | Związki, kompozycje i sposoby |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
US7947682B2 (en) * | 2004-12-29 | 2011-05-24 | University Of Southern California | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
JP5475235B2 (ja) | 2005-01-21 | 2014-04-16 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
SI1869020T1 (sl) | 2005-03-29 | 2011-02-28 | Icos Corp | Derivati heteroaril uree, ki so uporabni za inhibicijo chk1 |
WO2006110477A2 (en) * | 2005-04-07 | 2006-10-19 | Astrum Therapeutics Pty. Ltd. | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
WO2006117653A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Azole-based phosphodiesterase inhibitors |
MY146795A (en) * | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
GT200600207A (es) * | 2005-06-09 | 2007-01-15 | Novartis Ag | Proceso para la síntesis de compuestos orgánicos |
AU2013205820B2 (en) * | 2005-06-09 | 2015-11-26 | Novartis Ag | Process for the synthesis of organic compounds |
ES2580108T3 (es) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Compuestos de isoquinolina |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
WO2007070683A2 (en) * | 2005-12-15 | 2007-06-21 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7989455B2 (en) * | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
MX2008008152A (es) * | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Compuestos heterociclicos biciclicos. |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
NZ569327A (en) * | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
BRPI0710328A2 (pt) * | 2006-05-08 | 2011-08-09 | Ariad Pharma Inc | composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição |
KR101441365B1 (ko) * | 2006-05-08 | 2014-09-18 | 어리어드 파마슈티칼스, 인코포레이티드 | 모노시클릭 헤테로아릴 화합물 |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
AU2013273769B2 (en) * | 2006-11-15 | 2016-05-12 | Ym Biosciences Australia Pty Ltd | Inhibitors of Kinase Activity |
DK2848610T3 (da) * | 2006-11-15 | 2017-11-06 | Ym Biosciences Australia Pty | Hæmmere af kinaseaktivitet |
US7851500B2 (en) * | 2007-01-05 | 2010-12-14 | Bristol-Myers Squibb Company | Aminopyrazole kinase inhibitors |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
WO2009100536A1 (en) * | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
EP2328872A1 (en) * | 2008-06-19 | 2011-06-08 | AstraZeneca AB | Pyrazole compounds 436 |
CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
JP5424187B2 (ja) * | 2008-08-27 | 2014-02-26 | 学校法人 関西大学 | アシルアミノフェニル基を有する抗がん剤 |
KR20110073580A (ko) | 2008-10-17 | 2011-06-29 | 엑셀리시스, 인코포레이티드 | 스핑고신-1-포스페이트 수용체 길항제 |
EP2365809B8 (en) | 2008-11-12 | 2018-10-10 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
EP3235818A3 (en) | 2010-04-01 | 2018-03-14 | Critical Outcome Technologies, Inc. | Compounds for the treatment of hiv |
US9199918B2 (en) * | 2011-02-15 | 2015-12-01 | Georgetown University | Small molecule inhibitors of AGBL2 |
WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
CN103664924B (zh) * | 2012-09-18 | 2015-12-02 | 江西天新药业有限公司 | 3-[(4-氨基-2-甲基-5-嘧啶基)甲基]-5-(2-氯乙基)-4-甲基噻唑的制备方法 |
CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
EP3007689B1 (en) | 2013-01-10 | 2018-03-07 | Pulmokine, Inc. | Non-selective kinase inhibitors |
JP5934658B2 (ja) * | 2013-01-29 | 2016-06-15 | Jxエネルギー株式会社 | イミド−ウレア化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物 |
WO2014121883A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
CN106132403B (zh) | 2013-10-11 | 2020-04-28 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
AU2014348422B2 (en) | 2013-11-15 | 2019-02-14 | The Wistar Institute Of Anatomy And Biology | EBNA1 inhibitors and their method of use |
EP3756666A1 (en) * | 2013-12-24 | 2020-12-30 | Oncotartis Inc. | Nicotinamide compound for use in the treatment of cancer |
WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
CN113149885A (zh) | 2015-05-14 | 2021-07-23 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和使用其的方法 |
US9951019B2 (en) * | 2015-06-26 | 2018-04-24 | Regents Of The University Of Minnesota | Therapeutic compounds |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
KR102579582B1 (ko) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 키나아제 억제제 및 이의 중간체의 제조 방법 |
CA3035566A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
WO2018068739A1 (zh) * | 2016-10-13 | 2018-04-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基杂环类化合物 |
CA3041679A1 (en) | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
US11242338B2 (en) | 2018-05-17 | 2022-02-08 | The Wistar Institute | EBNA1 inhibitor crystalline forms, and methods of preparing and using same |
AU2019326768A1 (en) * | 2018-08-24 | 2021-03-18 | Agricultural University Of Athens (Aua) | 2,6-bis(((1H-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2,N6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
WO2020206583A1 (en) * | 2019-04-08 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Kinase inhibitors and uses thereof |
WO2020260871A1 (en) * | 2019-06-24 | 2020-12-30 | Benevolentai Bio Limited | New compounds and methods |
KR20220044753A (ko) * | 2019-07-25 | 2022-04-11 | 큐라데브 파마 프라이버트 리미티드 | 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제 |
CA3148769A1 (en) * | 2019-07-30 | 2021-02-04 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
CN113754541A (zh) * | 2020-06-02 | 2021-12-07 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH575397A5 (es) | 1971-11-09 | 1976-05-14 | Basf Ag | |
DE3148291A1 (de) * | 1981-12-05 | 1983-06-09 | Basf Ag, 6700 Ludwigshafen | Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
IE58870B1 (en) * | 1985-03-08 | 1993-11-17 | Leo Pharm Prod Ltd | Pyridine derivatives |
JPH083564B2 (ja) | 1986-07-25 | 1996-01-17 | 三菱化学株式会社 | 偏光フィルム |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
CA2203517A1 (en) | 1994-11-10 | 1996-05-23 | Alan M. Laibelman | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
EA000304B1 (ru) * | 1995-02-02 | 1999-04-29 | Смитклайн Бичам Плс | Производные индола как антагонисты рецептора 5-ht |
EP0731385B1 (en) * | 1995-03-09 | 2003-08-27 | Agfa-Gevaert | New photographic useful group releasing system |
JPH11503419A (ja) | 1995-03-29 | 1999-03-26 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼ阻害剤 |
WO1997003967A1 (en) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US5705499A (en) * | 1995-10-06 | 1998-01-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US6495526B2 (en) | 1996-01-23 | 2002-12-17 | Gpc Biotech, Inc. | Inhibitors of cell-cycle progression and uses related thereto |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
US5821243A (en) | 1996-07-22 | 1998-10-13 | Viropharma Incorporated | Compounds compositions and methods for treating influenza |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
AU6230098A (en) | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
FR2767827A1 (fr) | 1997-09-03 | 1999-02-26 | Adir | Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
CN1278725A (zh) | 1997-10-06 | 2001-01-03 | 巴斯福股份公司 | 茚并[1,2-c]-、萘并[1,2-c]-和苯并[6,7]芳庚并[1,2-c]吡唑类衍生物 |
YU22400A (sh) | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori |
JP2001521926A (ja) | 1997-11-04 | 2001-11-13 | ファイザー・プロダクツ・インク | 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換 |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
AP1258A (en) | 1998-02-26 | 2004-03-15 | Aventis Pharma Inc | 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines. |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
IL136588A0 (en) | 1998-02-27 | 2001-06-14 | Pfizer Prod Inc | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia |
AU749293B2 (en) * | 1998-05-15 | 2002-06-20 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
-
2001
- 2001-01-08 HN HN2001000008A patent/HN2001000008A/es unknown
- 2001-01-17 CO CO01003118A patent/CO5280047A1/es not_active Application Discontinuation
- 2001-01-17 PE PE2001000042A patent/PE20011047A1/es not_active Application Discontinuation
- 2001-01-18 AR ARP010100233A patent/AR029222A1/es unknown
- 2001-01-19 CA CA002394703A patent/CA2394703A1/en not_active Abandoned
- 2001-01-19 WO PCT/US2001/001723 patent/WO2001053274A1/en active Application Filing
- 2001-01-19 BR BR0108025-3A patent/BR0108025A/pt not_active IP Right Cessation
- 2001-01-19 JP JP2001553276A patent/JP2003529558A/ja not_active Abandoned
- 2001-01-19 AU AU2001234484A patent/AU2001234484A1/en not_active Abandoned
- 2001-01-19 GT GT200100014A patent/GT200100014A/es unknown
- 2001-01-19 MX MXPA02007102A patent/MXPA02007102A/es active IP Right Grant
- 2001-01-19 EP EP01906592A patent/EP1252146A1/en not_active Withdrawn
- 2001-01-19 US US09/764,306 patent/US6635641B2/en not_active Expired - Fee Related
- 2001-01-22 PA PA20018510201A patent/PA8510201A1/es unknown
-
2003
- 2003-07-17 US US10/621,979 patent/US20040092747A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001053274A1 (en) | 2001-07-26 |
BR0108025A (pt) | 2002-11-05 |
CA2394703A1 (en) | 2001-07-26 |
CO5280047A1 (es) | 2003-05-30 |
US6635641B2 (en) | 2003-10-21 |
MXPA02007102A (es) | 2003-01-28 |
JP2003529558A (ja) | 2003-10-07 |
PE20011047A1 (es) | 2001-11-06 |
HN2001000008A (es) | 2003-12-11 |
AU2001234484A1 (en) | 2001-07-31 |
AR029222A1 (es) | 2003-06-18 |
EP1252146A1 (en) | 2002-10-30 |
PA8510201A1 (es) | 2002-08-26 |
US20020103203A1 (en) | 2002-08-01 |
US20040092747A1 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200100014A (es) | Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo. | |
DOP2001000120A (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar e inhibir la proliferación celular | |
GT200400136A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular. | |
PA8608201A1 (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular | |
UY26190A1 (es) | Compuestos de tiazol y composiciones farmacéuticas para inhibir a las proteinquinasas y métodos para su utilización | |
ECSP055858A (es) | 2-(1h-indazol-6-ilamino)-compuestos benzamidas como inhibidores de la proteinquinasas útiles para el tratamiento de enfermedades oftálmicas | |
CO2022016377A2 (es) | Inhibidores de kras tricíclicos fusionados | |
SV2002000121A (es) | Compuestos indazol y composiciones farmaceuticas para inhibir la proteina quinasas y metodo para su uso | |
PA8547601A1 (es) | Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis | |
ES2194468T3 (es) | Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas. | |
BRPI0416936A (pt) | sistemas de anel de imidazo substituìdos e métodos | |
UY27199A1 (es) | Nuevos compuestos antiinflamatorios de triazolopiridinas | |
GT200100061A (es) | Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas. | |
BR0113286B1 (pt) | pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos. | |
BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
UY26877A1 (es) | Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes | |
AR030540A1 (es) | Compuestos antipicornavirales y composiciones, su uso farmaceutico, y materiales para su sintesis | |
PA8525701A1 (es) | Compuestos con nucleos heterociclico-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso | |
UY26666A1 (es) | Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y los materiales para su sintesis | |
PA8571601A1 (es) | Inhibidores selectivos de la ciclooxigenasa-2 | |
UY26547A1 (es) | Compuestos de amida y composiciones farmacéuticas para inhibir proteinquinasas, y su modo de empleo | |
ES2052622T3 (es) | Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos. | |
ECSP034533A (es) | Derivados sustituyentes 5-amino-1 penteno-3-ol |